Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time

Roger Stupp, Damien C. Weber, The role of radio- and chemotherapy in glioblastoma. Onkologie. ,vol. 28, pp. 315- 317 ,(2005) , 10.1159/000085575

Jörg Felsberg, Niklas Thon, Sabina Eigenbrod, Bettina Hentschel, Michael C. Sabel, Manfred Westphal, Gabriele Schackert, Friedrich Wilhelm Kreth, Torsten Pietsch, Markus Löffler, Michael Weller, Guido Reifenberger, Jörg C. Tonn, , Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas International Journal of Cancer. ,vol. 129, pp. 659- 670 ,(2011) , 10.1002/IJC.26083

J. Felsberg, M. Rapp, S. Loeser, R. Fimmers, W. Stummer, M. Goeppert, H.-J. Steiger, B. Friedensdorf, G. Reifenberger, M. C. Sabel, Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients Clinical Cancer Research. ,vol. 15, pp. 6683- 6693 ,(2009) , 10.1158/1078-0432.CCR-08-2801

Ilse Vlassenbroeck, Stéphane Califice, Annie-Claire Diserens, Eugenia Migliavacca, Josef Straub, Ivano Di Stefano, Fabrice Moreau, Marie-France Hamou, Isabelle Renard, Mauro Delorenzi, Bruno Flamion, James DiGuiseppi, Katja Bierau, Monika E. Hegi, Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma The Journal of Molecular Diagnostics. ,vol. 10, pp. 332- 337 ,(2008) , 10.2353/JMOLDX.2008.070169

Anna S. Berghoff, Harald Stefanits, Adelheid Woehrer, Harald Heinzl, Matthias Preusser, Johannes A. Hainfellner, Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. Clinical Neuropathology. ,vol. 32, pp. 148- 158 ,(2013) , 10.5414/NP300646

Nameeta Shah, Biaoyang Lin, Zita Sibenaller, Timothy Ryken, Hwahyung Lee, Jae-Geun Yoon, Steven Rostad, Greg Foltz, Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM PLoS ONE. ,vol. 6, pp. e16146- ,(2011) , 10.1371/JOURNAL.PONE.0016146

Monika E. Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M. Kros, Johannes A. Hainfellner, Warren Mason, Luigi Mariani, Jacoline E.C. Bromberg, Peter Hau, René O. Mirimanoff, J. Gregory Cairncross, Robert C. Janzer, Roger Stupp, MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma The New England Journal of Medicine. ,vol. 352, pp. 997- 1003 ,(2005) , 10.1056/NEJMOA043331

Annika Malmström, Bjørn Henning Grønberg, Christine Marosi, Roger Stupp, Didier Frappaz, Henrik Schultz, Ufuk Abacioglu, Björn Tavelin, Benoit Lhermitte, Monika E Hegi, Johan Rosell, Roger Henriksson, Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial Lancet Oncology. ,vol. 13, pp. 916- 926 ,(2012) , 10.1016/S1470-2045(12)70265-6

Wolfgang Wick, Michael Platten, Christoph Meisner, Jörg Felsberg, Ghazaleh Tabatabai, Matthias Simon, Guido Nikkhah, Kirsten Papsdorf, Joachim P Steinbach, Michael Sabel, Stephanie E Combs, Jan Vesper, Christian Braun, Jürgen Meixensberger, Ralf Ketter, Regine Mayer-Steinacker, Guido Reifenberger, Michael Weller, Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Lancet Oncology. ,vol. 13, pp. 707- 715 ,(2012) , 10.1016/S1470-2045(12)70164-X

Roger Stupp, Monika E Hegi, Warren P Mason, Martin J van den Bent, Martin JB Taphoorn, Robert C Janzer, Samuel K Ludwin, Anouk Allgeier, Barbara Fisher, Karl Belanger, Peter Hau, Alba A Brandes, Johanna Gijtenbeek, Christine Marosi, Charles J Vecht, Karima Mokhtari, Pieter Wesseling, Salvador Villa, Elizabeth Eisenhauer, Thierry Gorlia, Michael Weller, Denis Lacombe, J Gregory Cairncross, René-Olivier Mirimanoff, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncology. ,vol. 10, pp. 459- 466 ,(2009) , 10.1016/S1470-2045(09)70025-7